BioPharma Resources

Drug Trial Radar · NCT05890729

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 10, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Xentria, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations

Conditions

  • Pulmonary Sarcoidosis

Interventions

  • XTMAB-16 or PlaceboDrug

    Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study durationTime frame: Throughout Study Duration, 20 weeks

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Xentria Investigative Site

    Birmingham, Alabama

  • Xentria Investigative Site

    Denver, Colorado

  • Xentria Investigative Site

    Jacksonville, Florida

  • Xentria Investigative Site

    Chicago, Illinois

  • Xentria Investigative Site

    Chicago, Illinois

  • Xentria Investigative Site

    Iowa City, Iowa

  • Xentria Investigative Site

    Baltimore, Maryland

  • Xentria Investigative Site

    Detroit, Michigan

  • Xentria Investigative Site

    Minneapolis, Minnesota

  • Xentria Investigative Site

    Albany, New York

  • Xentria Investigative Site

    New York, New York

  • Xentria Investigative Site

    Greenville, North Carolina

  • Xentria Investigative Site

    Cincinnati, Ohio

  • Xentria Investigative Site

    Philadelphia, Pennsylvania

  • Xentria Investigative Site

    Charleston, South Carolina

  • Xentria Investigative Site

    Charlottesville, Virginia

  • Xentria Investigative Site

    Prague, Czechia

  • Xentria Investigative Site

    Aalborg, Denmark

  • Xentria Investigative Site

    Aarhus, Denmark

  • Xentria Investigative Site

    Odense, Denmark

  • Xentria Investigative Site

    Roskilde, Denmark

  • Xentria Investigative Site

    Vejle, Denmark

  • Xentria Investigative Site

    Bielsk Podlaski, Poland

  • Xentria Investigative Site

    Lodz, Poland

  • Xentria Investigative Site

    Barcelona, Spain

  • Xentria Investigative Site

    Barcelona, Spain

  • Xentria Investigative Site

    Seville, Spain

  • University Hospitals Coventry and Warwickshire NHS Trust

    Coventry, England, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, England, United Kingdom

  • King's College Hospital NHS Foundation Trust

    London, England, United Kingdom

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    Norwich, England, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, England, United Kingdom

  • NHS Tayside

    Perth, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.